{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:33:32Z","timestamp":1791898412454,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd014915","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000}}],"reference-count":75,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014915.pub2","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:11:37Z","timestamp":1686183097000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Cannabis-based medicines and medical cannabis for adults with cancer pain"],"prefix":"10.1002","volume":"2023","author":[{"given":"Winfried","family":"H\u00e4user","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine and Psychotherapy; Technische Universit\u00e4t M\u00fcnchen; M\u00fcnchen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Welsch","sequence":"additional","affiliation":[{"name":"Health Care Center for Pain Medicine and Mental Health; Saarbr\u00fccken Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Radbruch","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine; University Hospital of Bonn; Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Fisher","sequence":"additional","affiliation":[{"name":"Cochrane Pain, Palliative and Supportive Care Group; Pain Research Unit, Churchill Hospital; Oxford UK"},{"name":"Centre for Pain Research; University of Bath; Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae Frances","family":"Bell","sequence":"additional","affiliation":[{"name":"Emerita, Regional Centre of Excellence in Palliative Care; Haukeland University Hospital; Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Andrew","family":"Moore","sequence":"additional","affiliation":[{"name":"Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD014915.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/0003489415612801","article-title":"Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial","volume":"125","author":"C\u00f4t\u00e9","year":"2016","journal-title":"Annals of Otology, Rhinology, and Laryngology"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/2049463717710042","article-title":"Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies","volume":"11","author":"Fallon","year":"2017","journal-title":"British Journal of Pain"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/2049463717710042","article-title":"Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies","volume":"11","author":"Fallon","year":"2017","journal-title":"British Journal of Pain"},{"issue":"7","key":"10.1002\/14651858.CD014915.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1200\/JCO.22.","article-title":"Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD)","volume":"41","author":"Hardy","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cpt1978242223","article-title":"Effect of benzopyranoperidine, a delta-9-THC congener, on pain","volume":"24","author":"Jochimsen","year":"1978","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","article-title":"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain","volume":"39","author":"Johnson","year":"2010","journal-title":"Journal of Pain and Symptom Management"},{"issue":"2","key":"10.1002\/14651858.CD014915.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jpainsymman.2017.09.001","article-title":"Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain","volume":"55","author":"Lichtman","year":"2018","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpainsymman.2013.02.018","article-title":"A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain","volume":"47","author":"Lynch","year":"2014","journal-title":"Journal Pain and Symptom Management"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/cpt197518184","article-title":"The analgesic properties of delta-9-tetrahydrocannabinol and codeine","volume":"18","author":"Brunk","year":"1975","journal-title":"Clinical Pharmacology & Therapy"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/j.1552-4604.1975.tb02348.x","article-title":"Analgesic effect of delta-9-tetrahydrocannabinol","volume":"15","author":"Brunk","year":"1975","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jpain.2012.01.003","article-title":"Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial","volume":"13","author":"Portenoy","year":"2012","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt1978234397","article-title":"Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain","volume":"23","author":"Staquet","year":"1978","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/cpt1978234397","article-title":"Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain","volume":"23","author":"Staquet","year":"1978","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD014915.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1002\/14651858.CD014915.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1007\/s00520-021-06301-x","article-title":"A randomised trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction","volume":"29","author":"Zylla","year":"2021","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0016|cit16","unstructured":"A phase I\/II double-blind, randomised controlled trial assessing effect of medicinal cannabis on quality of life and symptom control in advanced cancer anzctr.org.au\/ACTRN12619001534178.aspx"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0017|cit17","unstructured":"NanaBis\u2122 an oro-buccal administered delta9-tetrahydrocannabinol (d9-THC) and cannabidiol (CBD) medicine for the management of chronic pain from metastatic bone cancer anzctr.org.au\/ACTRN12621001302842.aspx"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0018|cit18","unstructured":"A double-blind, randomized phase 1\/2 study to assess the efficacy and safety of BCT-521 versus placebo for pain associated with cancer inpatients already receiving standard of care treatment with opioids www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001382-32\/PL\/"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1186\/s13063-020-04541-6","article-title":"Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"21","author":"Hardy","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0020|cit20","unstructured":"Safety and efficacy of inhaled cannabis for the uncontrolled pain relief in patients with advanced cancer (PLENITUDE) clinicaltrials.gov\/ct2\/show\/NCT04042545"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejim.2018.01.001","article-title":"Medical use of cannabis and cannabinoids containing products \u2013 regulations in Europe and North America","volume":"49","author":"Abuhasira","year":"2018","journal-title":"European Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00103-008-0648-9","article-title":"Pharmacoepidemiological research with large health databases","volume":"51","author":"Andersohn","year":"2008","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"E755","DOI":"10.36076\/ppj.20.5.E755","article-title":"Efficacy of cannabis based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Aviram","year":"2017","journal-title":"Pain Physician"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/ph13120435","article-title":"Short-term medical cannabis treatment regimens produced beneficial effects among palliative cancer patients","volume":"13","author":"Aviram","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejim.2018.01.023","article-title":"Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer","volume":"49","author":"Bar-Lev Schleider","year":"2018","journal-title":"European Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective","volume":"106","author":"Basch","year":"2014","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.21037\/apm.2017.08.05","article-title":"A selective review of medical cannabis in cancer pain management","volume":"6","author":"Blake","year":"2017","journal-title":"Annals Palliative Medicine"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/bmjspcare-2019-002032","article-title":"Cannabinoids for adult cancer-related pain: systematic review and meta-analysis","volume":"10","author":"Boland","year":"2020","journal-title":"BMJ Supportive and Palliative Care"},{"issue":"8","key":"10.1002\/14651858.CD014915.pub2-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004959.pub4","article-title":"Opioids compared to placebo or other treatments for chronic low-back pain","author":"Chaparro","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0030|cit30","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/annonc\/mdw097","article-title":"Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \"real life\" trial on the variability of response to opioids","volume":"27","author":"Corli","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1517\/14656566.2014.918102","article-title":"Dronabinol and chronic pain: importance of mechanistic considerations","volume":"15","author":"De Vries","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jama.2014.8166","article-title":"Association between analytic strategy and estimates of treatment outcomes in meta-analyses","volume":"312","author":"Dechartres","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0035|cit35","unstructured":"European Medicines Agency Epydiolex (2019) Available from www.ema.europa.eu\/en\/medicines\/human\/EPAR\/epidyolex"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11136-013-0443","article-title":"Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences","volume":"23","author":"Fayers","year":"2014","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014915.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/j.pain.0000000000001929","article-title":"Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials","volume":"162","author":"Fisher","year":"2021","journal-title":"Pain"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3899\/jrheum.181120","article-title":"Position statement: a pragmatic approach for medical cannabis and patients with rheumatic diseases","volume":"46","author":"Fitzcharles","year":"2019","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0040|cit40","unstructured":"Sativex oromucosal spray www.medicines.org.uk\/emc\/product\/602\/smp"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0041|cit41","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0042|cit42","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from handbook: training.cochrane.org\/handbook\/archive\/v6.1"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0043|cit43","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroscience.2011.11.020","article-title":"Contributions of endocannabinoid signalling to psychiatric disorders in humans: genetic and biochemical evidence","volume":"204","author":"Hillard","year":"2012","journal-title":"Neuroscience"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/ejp.1297","article-title":"European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management","volume":"22","author":"H\u00e4user","year":"2018","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00482-019-037","article-title":"Efficacy, tolerability and safety of cannabis-based medicines for cancer pain. A systematic review with meta-analysis of randomised controlled trials","volume":"33","author":"H\u00e4user","year":"2019","journal-title":"Schmerz"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0047|cit47","unstructured":"International Council for Harmonisation Medical dictionary for regulatory activities version 23.1 (2020) Available from www.meddra.org\/how-to-use\/support-documentation\/english"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1155\/2001\/469629","article-title":"Medicinal use of cannabis: history and current status","volume":"6","author":"Kalant","year":"2001","journal-title":"Pain Research & Management"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"175883591986636","DOI":"10.1177\/1758835919866362","article-title":"Opportunities for cannabis in supportive care in cancer","volume":"11","author":"Kleckner","year":"2019","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ejp.1147","article-title":"Availability and approval of cannabis-based medicines for chronic pain management and palliative\/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation","volume":"22","author":"Krcevski-Skvarc","year":"2018","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pain.2012.09.017","article-title":"Amygdala activity contributes to the dissociative effect of cannabis on pain perception","volume":"134","author":"Lee","year":"2013","journal-title":"Pain"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3747\/co.25.3983","article-title":"Rates of cannabis use in patients with cancer","volume":"25","author":"Martell","year":"2018","journal-title":"Current Oncology"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0053|cit53","volume-title":"An Evidence-Based Resource for Pain Relief","author":"McQuay","year":"1998"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","article-title":"Size is everything \u2013 large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects","volume":"78","author":"Moore","year":"1998","journal-title":"Pain"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0056|cit56","first-page":"15","volume-title":"Systematic Reviews in Pain Research: Methodology Refined","author":"Moore","year":"2008"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs \u2013 no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anesthesia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014915.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1097\/j.pain.0000000000001941","article-title":"Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews","volume":"62","author":"Moore","year":"2021","journal-title":"Pain"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0059|cit59","unstructured":"Oregon Health Authority Opioid calculator www.oregonpainguidance.org\/opioidmedcalculator\/"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1038\/525S6a","article-title":"Drug development: the treasure chest","volume":"525","author":"Owens","year":"2015","journal-title":"Nature"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00482-020-00458-w","article-title":"Cannabidiol","volume":"34","author":"Radbruch","year":"2020","journal-title":"Schmerz"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0062|cit62","unstructured":"Review Manager 5 (RevMan 5) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0063|cit63","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0064|cit64","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Elie AE Skoetz N Chapter 14. Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from handbook: training.cochrane.org\/handbook\/archive\/v6.1"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/PR9.000000000000076","article-title":"A protocol for the systematic review and meta-analysis of studies in which cannabinoids were tested for antinociceptive effects in animal models of pathological or injury-related persistent pain","volume":"4","author":"Soliman","year":"2019","journal-title":"Pain Reports"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies","volume":"158","author":"Stockings","year":"2018","journal-title":"Pain"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","article-title":"Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Swarm","year":"2019","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"den Beuken-van Everdingen","year":"2016","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.outlook.2017.08.012","article-title":"The use of cannabis in response to the opioid crisis: a review of the literature","volume":"66","author":"Vyas","year":"2018","journal-title":"Nursing Outlook"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"n1034","DOI":"10.1136\/bmj.n1034","article-title":"Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials","volume":"374","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0071|cit71","unstructured":"World Health Organization WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents, 2019 Available from www.who.int\/ncds\/management\/palliative-care\/cancer-pain-guidelines\/en"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0072|cit72","unstructured":"World Health Organization Cancer, 2021 Available from www.who.int\/health-topics\/cancer#tab=tab_1"},{"issue":"7","key":"10.1002\/14651858.CD014915.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012592","article-title":"Opioids for cancer pain \u2013 an overview of Cochrane Reviews","author":"Wiffen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014915.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/1874467212666190215112036","article-title":"New insights in cannabinoid receptor structure and signaling","volume":"12","author":"Ye","year":"2019","journal-title":"Current Molecular Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD014915.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014915","article-title":"Cannabis-based medicines and medical cannabis for adults with cancer pain","author":"H\u00e4user","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T12:46:31Z","timestamp":1725453991000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014915.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":75,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014915.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]}}}